Controlled Extension of Oral Antidiabetic Therapy on Former Insulin Dependent Diabetics by Means of the Combined I.v. Glibenclamide-glucose-response-test

Overview

Journal Diabetologia

Specialty Endocrinology

Date 1972 Feb 1

PMID 4623790

Citations 2

Authors

E F Pfeiffer

S Raptis

Affiliations

Soon will be listed here.

Citing Articles

Human C-peptide. Part II: Clinical studies.

Beischer W, Heinze E, Keller L, Raptis S, Kerner W, Pfeiffer E Klin Wochenschr. 1976; 54(15):717-25.

PMID: 824496 DOI: 10.1007/BF01470463.

[Human C-peptide. Part III: dynamics of secretion of beta-cells in adult diabetics following glibenclamide-glucose i.v. (human C-peptide III) (author's transl)].

Beischer W, Raptis S, Keller L, Maas M, Beischer B, Feilen K Klin Wochenschr. 1978; 56(3):111-20.

PMID: 415175 DOI: 10.1007/BF01478566.

References

DOST F . [Flow equilibrium in the circulating blood]. Dtsch Med Wochenschr. 1962; 87:1833-40. DOI: 10.1055/s-0028-1114027. View

Pfeiffer E, Pfeiffer M, DITSCHUNEIT H, Ahn C . Clinical and experimental studies of insulin secretion following tolbutamide and metahexamide administration. Ann N Y Acad Sci. 1959; 82:479-95. DOI: 10.1111/j.1749-6632.1959.tb44927.x. View

Unger R, Madison L . A new diagnostic procedure for mild diabetes mellitus; evaluation of an intravenous tolbutamide response test. Diabetes. 1958; 7(6):455-61. DOI: 10.2337/diab.7.6.455. View

PFEFFER K, FUCHS K, Michel W, FOERDER H . [Effects of intravenous & oral N-sulfanilyl-N-butyl urea (BZ 55) on blood sugar in diabetics and persons with normal metabolism]. Arztl Wochensch. 1957; 12(12):260-3. View

Heding L . Determination of free and antibody-bound insulin in insulin treated diabetic patients. Horm Metab Res. 1969; 1(3):145-6. DOI: 10.1055/s-0028-1096835. View

Melani F, DITSCHUNEIT H, Bartelt K, Friedrich H, Pfeiffer E . [On radio-immunologic determination of insulin in blood]. Klin Wochenschr. 1965; 43(18):1000-7. DOI: 10.1007/BF01747863. View

Pfeiffer E, SCHOFFLING K, Steigerwald H, DITSCHUNEIT H, Heubel F . [Significance of a single dose as an indication for the suitability of oral diabetic therapy]. Dtsch Med Wochenschr. 1957; 82(36):1544 passim. DOI: 10.1055/s-0028-1116932. View

FAJANS S, Schneider J, Schteingart D, CONN J . The diagnostic value of sodium tolbutamide in hypoglycemic states. J Clin Endocrinol Metab. 1961; 21:371-86. DOI: 10.1210/jcem-21-4-371. View

Mehnert H, Karg E . [Glybenclamide (HB 419): a new oral antidiabetic agent of the sulfonylurea group]. Dtsch Med Wochenschr. 1969; 94(16):819-24. DOI: 10.1055/s-0028-1111124. View

10.

Pfeiffer E . [Current pathophysiological and clinical aspects of the mode of action of blood glucose lowering sulfonamides]. Acta Diabetol Lat. 1969; 6 Suppl 1:477-502. View

11.

CAMERINI-DAVALOS R, Marble A, Root H . Clinical experience with carbutamide (BZ-55); a progress report. Diabetes. 1957; 6(1):74-7; discussion, 85-90. DOI: 10.2337/diab.6.1.74. View

12.

CONARD V . [Determination of glucose assimilation; theoretical bases and clinical applications]. Acta Gastroenterol Belg. 1955; 18(10):803-45; concl. View

13.

GITTLER R, ZUCKER G, EISINGER R, Stoller N . Amelioration of diabetes mellitus by an insulinoma. N Engl J Med. 1958; 258(19):932-5. DOI: 10.1056/NEJM195805082581903. View